QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Clinical Trials For Cellceutix Corp. (CTIX) Cancer Drug Kevetrin Going Active This Week 0 comments
    Oct 8, 2012 2:09 PM | about stocks: CTIX

    Cellceutix is a clinical stage biopharmaceutical company focused on the development of a pipeline of small molecule drugs to treat unmet medical conditions, including cancers and autoimmune diseases. The company's flagship compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers that have proven resistant to current cancer therapies.

    In more than 50% of all human cancers, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are more than 10 million people with tumors that have inactivated p53 and a similar number have p53 pathways that are partially abrogated. This has left cancer researchers with the task of searching for therapies that could restore the protein's protective function. Kevetrin appears to do so most of the time.

    The company reported today that it has been advised that the clinical trials for its novel anti-cancer drug candidate, Kevetrin, will be going active this week. The trials are being conducted at Harvard Cancer Centers Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Both centers are ready to begin the recruitment, enrollment, and dosing processes.

    The clinical trial is titled "A phase1, open-label, dose-escalation, safety, pharmacokinetic and p

    pharmacodynamic study of Kevetrin (Thioureidobutyronitrile) administered intravenously, in patients with advanced solid tumors." Cellceutix has been advised to expect the first dosing of Kevetrin to be administered within approximately one week of activating the trial.

    For additional information about Cellceutix, Kevetrin, and the company's seven other drug compounds, visit the company's website at cellceutix.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: CTIX
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.